Shanghai Pharmaceuticals (601607) H1 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached RMB 147.47 billion, up 4.15% year-over-year, with industrial and commercial segments both contributing to growth.

• Net profit attributable to shareholders was RMB 3.50 billion, down 21.40% year-over-year, mainly due to one-off items; adjusted net profit excluding non-recurring items rose 1.65%.

• Operating cash flow was robust at RMB 4.45 billion, up 349.78% year-over-year.

• R&D investment totaled RMB 1.05 billion, representing 7.98% of industrial segment sales.

Financial highlights

• Gross profit margin remained stable; operating profit was RMB 5.63 billion, down 17.44% year-over-year.

• Basic and diluted EPS were RMB 0.95, down 20.83% year-over-year.

• Net assets attributable to shareholders increased 3.24% to RMB 78.35 billion.

• Cash and cash equivalents at period-end were RMB 32.28 billion.

• Non-recurring gains totaled RMB 1.03 billion, mainly from asset disposals and government grants.

Outlook and guidance

• The company will focus on quality growth, innovation, and operational efficiency in H2 2026.

• Emphasis on R&D, digital transformation, and supply chain upgrades to drive future performance.